# Clinical References and Evidence Base

**Version:** 1.0
**Last Updated:** October 2025
**Purpose:** Comprehensive literature citations for clinical scoring systems and prognostic calculators used in the Discharge Summary Generator (DCS)

---

## Table of Contents

1. [Functional Scoring Systems](#functional-scoring-systems)
2. [Neurological Assessment Scales](#neurological-assessment-scales)
3. [Outcome Prediction Models](#outcome-prediction-models)
4. [Pathology-Specific Prognostic Tools](#pathology-specific-prognostic-tools)
5. [Quality of Life Measures](#quality-of-life-measures)
6. [Implementation Guidelines](#implementation-guidelines)
7. [Clinical Validation](#clinical-validation)

---

## Functional Scoring Systems

### 1. Karnofsky Performance Status (KPS)

**Scale Range:** 0-100 (higher scores indicate better functional status)

**Original Reference:**
- Karnofsky DA, Burchenal JH. "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." In: MacLeod CM (Ed), *Evaluation of Chemotherapeutic Agents*. Columbia Univ Press. 1949. pp. 196.

**Key Validation Studies:**
- Schag CC, Heinrich RL, Ganz PA. "Karnofsky performance status revisited: reliability, validity, and guidelines." *J Clin Oncol.* 1984;2(3):187-193.
  - DOI: 10.1200/JCO.1984.2.3.187
  - PMID: 6699671

- Mor V, Laliberte L, Morris JN, Wiemann M. "The Karnofsky Performance Status Scale: An examination of its reliability and validity in a research setting." *Cancer.* 1984;53(9):2002-2007.
  - DOI: 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W
  - PMID: 6704925

**Clinical Application:**
- Primarily used in oncology and neuro-oncology
- Validated for glioblastoma, meningioma, and other CNS tumors
- Prognostic factor in treatment decision-making

**Interpretation Guidelines:**
- 100: Normal; no complaints; no evidence of disease
- 90: Able to carry on normal activity; minor signs or symptoms
- 80: Normal activity with effort; some signs or symptoms
- 70: Cares for self; unable to carry on normal activity
- 60: Requires occasional assistance but able to care for most needs
- 50: Requires considerable assistance and frequent medical care
- 40: Disabled; requires special care and assistance
- 30: Severely disabled; hospitalization indicated
- 20: Very sick; hospitalization necessary; active supportive treatment
- 10: Moribund; fatal processes progressing rapidly
- 0: Dead

---

### 2. ECOG Performance Status (Eastern Cooperative Oncology Group)

**Scale Range:** 0-5 (lower scores indicate better functional status)

**Original Reference:**
- Oken MM, Creech RH, Tormey DC, et al. "Toxicity and response criteria of the Eastern Cooperative Oncology Group." *Am J Clin Oncol.* 1982;5(6):649-655.
  - DOI: 10.1097/00000421-198212000-00014
  - PMID: 7165009

**Key Validation Studies:**
- Buccheri G, Ferrigno D, Tamburini M. "Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution." *Eur J Cancer.* 1996;32A(7):1135-1141.
  - DOI: 10.1016/0959-8049(95)00664-8
  - PMID: 8758243

- SÃ¸rensen JB, Klee M, Palshof T, Hansen HH. "Performance status assessment in cancer patients: An inter-observer variability study." *Br J Cancer.* 1993;67(4):773-775.
  - DOI: 10.1038/bjc.1993.140
  - PMID: 8471434

**Clinical Application:**
- Widely used in oncology clinical trials
- Validated for brain tumors, systemic malignancies
- Simplified alternative to KPS

**Interpretation Guidelines:**
- 0: Fully active, able to carry on all pre-disease activities
- 1: Restricted in physically strenuous activity but ambulatory
- 2: Ambulatory and capable of all self-care but unable to work
- 3: Capable of only limited self-care; confined to bed/chair >50% of waking hours
- 4: Completely disabled; cannot carry on any self-care; confined to bed/chair
- 5: Dead

---

### 3. Modified Rankin Scale (mRS)

**Scale Range:** 0-6 (lower scores indicate better functional status)

**Original References:**
- Rankin J. "Cerebral vascular accidents in patients over the age of 60: II. Prognosis." *Scott Med J.* 1957;2(5):200-215.
  - DOI: 10.1177/003693305700200504
  - PMID: 13432835

- van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. "Interobserver agreement for the assessment of handicap in stroke patients." *Stroke.* 1988;19(5):604-607.
  - DOI: 10.1161/01.STR.19.5.604
  - PMID: 3363593

**Key Validation Studies:**
- Banks JL, Marotta CA. "Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials." *Stroke.* 2007;38(3):1091-1096.
  - DOI: 10.1161/01.STR.0000258355.23810.c6
  - PMID: 17272767

- Quinn TJ, Dawson J, Walters MR, Lees KR. "Reliability of the modified Rankin Scale: a systematic review." *Stroke.* 2009;40(10):3393-3395.
  - DOI: 10.1161/STROKEAHA.109.557256
  - PMID: 19679846

**Clinical Application:**
- Gold standard for measuring stroke outcome
- Used in SAH, AVM, stroke, and other cerebrovascular conditions
- Primary endpoint in most stroke clinical trials

**Interpretation Guidelines:**
- 0: No symptoms
- 1: No significant disability; able to carry out all usual activities
- 2: Slight disability; unable to carry out all previous activities but able to look after own affairs
- 3: Moderate disability; requires some help but able to walk unassisted
- 4: Moderately severe disability; unable to walk without assistance
- 5: Severe disability; bedridden, incontinent, requires constant nursing care
- 6: Dead

**Good Outcome Definition:**
- mRS 0-2 is typically defined as "good functional outcome"
- mRS 0-3 sometimes used in elderly populations or severe initial deficits

---

## Neurological Assessment Scales

### 4. Glasgow Coma Scale (GCS)

**Scale Range:** 3-15 (higher scores indicate better consciousness level)

**Original Reference:**
- Teasdale G, Jennett B. "Assessment of coma and impaired consciousness: A practical scale." *Lancet.* 1974;304(7872):81-84.
  - DOI: 10.1016/S0140-6736(74)91639-0
  - PMID: 4136544

**Key Validation Studies:**
- Teasdale G, Murray G, Parker L, Jennett B. "Adding up the Glasgow Coma Scale." *Acta Neurochir Suppl (Wien).* 1979;28(1):13-16.
  - PMID: 290137

- Reith FC, Van den Brande R, Synnot A, et al. "The reliability of the Glasgow Coma Scale: a systematic review." *Intensive Care Med.* 2016;42(1):3-15.
  - DOI: 10.1007/s00134-015-4124-3
  - PMID: 26564211

**Clinical Application:**
- Universal standard for assessing consciousness in trauma
- Used in SAH, traumatic brain injury, stroke, GBM
- Component of multiple prognostic models (WFNS, Hunt-Hess)

**Interpretation Guidelines:**
- **Eye Opening (E):**
  - 4: Spontaneous
  - 3: To voice
  - 2: To pain
  - 1: None

- **Verbal Response (V):**
  - 5: Oriented
  - 4: Confused
  - 3: Inappropriate words
  - 2: Incomprehensible sounds
  - 1: None

- **Motor Response (M):**
  - 6: Obeys commands
  - 5: Localizes to pain
  - 4: Withdraws from pain
  - 3: Flexion to pain (decorticate)
  - 2: Extension to pain (decerebrate)
  - 1: None

**Severity Classification:**
- Severe: GCS 3-8
- Moderate: GCS 9-12
- Minor: GCS 13-15

---

### 5. NIH Stroke Scale (NIHSS)

**Scale Range:** 0-42 (lower scores indicate less severe neurological deficit)

**Original Reference:**
- Brott T, Adams HP Jr, Olinger CP, et al. "Measurements of acute cerebral infarction: a clinical examination scale." *Stroke.* 1989;20(7):864-870.
  - DOI: 10.1161/01.STR.20.7.864
  - PMID: 2749846

**Key Validation Studies:**
- Lyden P, Brott T, Tilley B, et al. "Improved reliability of the NIH Stroke Scale using video training." *Stroke.* 1994;25(11):2220-2226.
  - DOI: 10.1161/01.STR.25.11.2220
  - PMID: 7974549

- Goldstein LB, Samsa GP. "Reliability of the National Institutes of Health Stroke Scale: Extension to non-neurologists in the context of a clinical trial." *Stroke.* 1997;28(2):307-310.
  - DOI: 10.1161/01.STR.28.2.307
  - PMID: 9040680

- Adams HP Jr, Davis PH, Leira EC, et al. "Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST)." *Neurology.* 1999;53(1):126-131.
  - DOI: 10.1212/WNL.53.1.126
  - PMID: 10408548

**Clinical Application:**
- Standard stroke severity assessment worldwide
- Predicts outcome in ischemic stroke and hemorrhagic stroke
- Used for tPA eligibility and mechanical thrombectomy decisions

**Interpretation Guidelines:**
- 0: No stroke symptoms
- 1-4: Minor stroke
- 5-15: Moderate stroke
- 16-20: Moderate to severe stroke
- 21-42: Severe stroke

**Prognostic Value:**
- Baseline NIHSS strongly predicts 3-month mRS
- Every 1-point increase in NIHSS associated with decreased likelihood of good outcome
- NIHSS >20 associated with high mortality

---

### 6. ASIA Impairment Scale (American Spinal Injury Association)

**Scale Range:** A-E (Grade E indicates normal function)

**Original Reference:**
- American Spinal Injury Association. "International Standards for Neurological Classification of Spinal Cord Injury." Chicago, IL: American Spinal Injury Association; 2019 (Updated periodically).
  - Available at: https://asia-spinalinjury.org/

**Key Validation Studies:**
- Marino RJ, Barros T, Biering-Sorensen F, et al. "International standards for neurological classification of spinal cord injury." *J Spinal Cord Med.* 2003;26 Suppl 1:S50-S56.
  - DOI: 10.1080/10790268.2003.11754575
  - PMID: 16296564

- Kirshblum SC, Burns SP, Biering-Sorensen F, et al. "International standards for neurological classification of spinal cord injury (revised 2011)." *J Spinal Cord Med.* 2011;34(6):535-546.
  - DOI: 10.1179/204577211X13207446293695
  - PMID: 22118251

**Clinical Application:**
- Universal classification for spinal cord injuries
- Determines sensory and motor levels
- Predicts functional recovery potential

**Interpretation Guidelines:**
- **A (Complete):** No sensory or motor function preserved in sacral segments S4-S5
- **B (Sensory Incomplete):** Sensory but not motor function preserved below neurological level, including S4-S5
- **C (Motor Incomplete):** Motor function preserved below neurological level; >50% of key muscle functions below neurological level have grade <3
- **D (Motor Incomplete):** Motor function preserved below neurological level; â¥50% of key muscle functions below neurological level have grade â¥3
- **E (Normal):** Sensory and motor functions are normal in all segments

**Prognostic Significance:**
- ASIA A at admission: 10-15% convert to incomplete
- ASIA B: 50-60% gain motor function
- ASIA C: 75-85% become ambulatory
- ASIA D: 95%+ maintain ambulation

---

## Quality of Life Measures

### 7. Barthel Index

**Scale Range:** 0-100 (higher scores indicate greater independence)

**Original Reference:**
- Mahoney FI, Barthel DW. "Functional evaluation: The Barthel Index." *Md State Med J.* 1965;14:61-65.
  - PMID: 14258950

**Key Validation Studies:**
- Collin C, Wade DT, Davies S, Horne V. "The Barthel ADL Index: a reliability study." *Int Disabil Stud.* 1988;10(2):61-63.
  - DOI: 10.3109/09638288809164103
  - PMID: 3403500

- Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett JE. "Stroke rehabilitation: analysis of repeated Barthel index measures." *Arch Phys Med Rehabil.* 1979;60(1):14-17.
  - PMID: 420565

**Clinical Application:**
- Measures activities of daily living (ADL)
- Used in stroke, spinal cord injury, neurosurgical rehabilitation
- Predicts discharge disposition

**Assessment Domains:**
1. Feeding
2. Bathing
3. Grooming
4. Dressing
5. Bowel control
6. Bladder control
7. Toilet use
8. Transfers (bed to chair)
9. Mobility (on level surfaces)
10. Stairs

**Interpretation:**
- 0-20: Total dependence
- 21-60: Severe dependence
- 61-90: Moderate dependence
- 91-99: Slight dependence
- 100: Independent

---

### 8. Spinal Cord Independence Measure (SCIM)

**Scale Range:** 0-100 (higher scores indicate greater independence)

**Original Reference:**
- Catz A, Itzkovich M, Agranov E, Ring H, Tamir A. "SCIM--spinal cord independence measure: a new disability scale for patients with spinal cord lesions." *Spinal Cord.* 1997;35(12):850-856.
  - DOI: 10.1038/sj.sc.3100504
  - PMID: 9429264

**Updated Version (SCIM III):**
- Itzkovich M, Gelernter I, Biering-Sorensen F, et al. "The Spinal Cord Independence Measure (SCIM) version III: reliability and validity in a multi-center international study." *Disabil Rehabil.* 2007;29(24):1926-1933.
  - DOI: 10.1080/09638280601046302
  - PMID: 17852230

**Clinical Application:**
- Specifically designed for spinal cord injury
- More sensitive than Barthel Index for SCI population
- Evaluates self-care, respiration, sphincter management, mobility

**Assessment Domains:**
1. Self-care (0-20 points)
   - Feeding, bathing, dressing, grooming
2. Respiration and sphincter management (0-40 points)
   - Breathing, bladder, bowel management
3. Mobility (0-40 points)
   - Room and toilet mobility, indoors/outdoors mobility

**Advantages over Barthel:**
- Captures respiratory dependence
- More detailed mobility assessment
- Specifically validated for SCI population

---

## Outcome Prediction Models

### 9. Hunt-Hess Classification (Subarachnoid Hemorrhage)

**Scale Range:** Grade I-V (higher grades indicate worse condition)

**Original Reference:**
- Hunt WE, Hess RM. "Surgical risk as related to time of intervention in the repair of intracranial aneurysms." *J Neurosurg.* 1968;28(1):14-20.
  - DOI: 10.3171/jns.1968.28.1.0014
  - PMID: 5635959

**Key Validation Studies:**
- Rosen DS, Macdonald RL. "Subarachnoid hemorrhage grading scales: A systematic review." *Neurocrit Care.* 2005;2(2):110-118.
  - DOI: 10.1385/NCC:2:2:110
  - PMID: 16159052

- Oshiro EM, Walter KA, Piantadosi S, Witham TF, Tamargo RJ. "A new subarachnoid hemorrhage grading system based on the Glasgow Coma Scale: a comparison with Hunt and Hess and World Federation of Neurological Surgeons Scales in a clinical series." *Neurosurgery.* 1997;41(1):140-147.
  - DOI: 10.1097/00006123-199707000-00029
  - PMID: 9218306

**Clinical Application:**
- Predicts surgical risk and outcome in aneurysmal SAH
- Guides treatment timing decisions
- Correlates with mortality and morbidity

**Interpretation Guidelines:**
- **Grade I:** Asymptomatic or minimal headache and slight nuchal rigidity
- **Grade II:** Moderate to severe headache, nuchal rigidity, cranial nerve palsy
- **Grade III:** Drowsiness, confusion, or mild focal deficit
- **Grade IV:** Stupor, moderate to severe hemiparesis, early decerebrate rigidity
- **Grade V:** Deep coma, decerebrate rigidity, moribund appearance

**Prognostic Value:**
- Grade I-II: 70-90% good outcome
- Grade III: 50-60% good outcome
- Grade IV: 30-40% good outcome
- Grade V: <10% good outcome

---

### 10. World Federation of Neurological Surgeons (WFNS) Scale

**Scale Range:** Grade I-V (higher grades indicate worse condition)

**Original Reference:**
- Drake CG. "Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale." *J Neurosurg.* 1988;68(6):985-986.
  - DOI: 10.3171/jns.1988.68.6.0985

- Teasdale GM, Drake CG, Hunt W, et al. "A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies." *J Neurol Neurosurg Psychiatry.* 1988;51(11):1457.
  - DOI: 10.1136/jnnp.51.11.1457
  - PMID: 3236024

**Key Validation Studies:**
- Rosen DS, Macdonald RL. "Subarachnoid hemorrhage grading scales: A systematic review." *Neurocrit Care.* 2005;2(2):110-118.
  - DOI: 10.1385/NCC:2:2:110
  - PMID: 16159052

**Clinical Application:**
- Based on GCS and presence of focal motor deficit
- More objective than Hunt-Hess (uses GCS)
- Widely used in clinical trials

**Interpretation Guidelines:**
- **Grade I:** GCS 15, no motor deficit
- **Grade II:** GCS 13-14, no motor deficit
- **Grade III:** GCS 13-14, with motor deficit
- **Grade IV:** GCS 7-12, with or without motor deficit
- **Grade V:** GCS 3-6, with or without motor deficit

---

### 11. Fisher Scale (SAH Blood Volume)

**Scale Range:** Grade 1-4 (higher grades indicate more blood and higher vasospasm risk)

**Original Reference:**
- Fisher CM, Kistler JP, Davis JM. "Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning." *Neurosurgery.* 1980;6(1):1-9.
  - DOI: 10.1227/00006123-198001000-00001
  - PMID: 7354892

**Modified Fisher Scale:**
- Claassen J, Bernardini GL, Kreiter K, et al. "Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited." *Stroke.* 2001;32(9):2012-2020.
  - DOI: 10.1161/hs0901.095677
  - PMID: 11546890

**Clinical Application:**
- Predicts vasospasm risk after SAH
- Modified Fisher scale has better predictive value
- Guides vasospasm monitoring intensity

**Original Fisher Scale:**
- **Grade 1:** No blood detected
- **Grade 2:** Diffuse thin layer (<1mm)
- **Grade 3:** Thick clot (>1mm) or localized clot
- **Grade 4:** Diffuse or no SAH with IVH or parenchymal extension

**Modified Fisher Scale:**
- **Grade 0:** No SAH or IVH
- **Grade 1:** Minimal SAH, no IVH
- **Grade 2:** Minimal SAH, with IVH
- **Grade 3:** Thick SAH, no IVH (highest vasospasm risk)
- **Grade 4:** Thick SAH, with IVH

**Vasospasm Risk:**
- Modified Fisher Grade 3-4: 40-70% symptomatic vasospasm risk

---

### 12. Spetzler-Martin AVM Grading Scale

**Scale Range:** Grade I-V (higher grades indicate higher surgical risk)

**Original Reference:**
- Spetzler RF, Martin NA. "A proposed grading system for arteriovenous malformations." *J Neurosurg.* 1986;65(4):476-483.
  - DOI: 10.3171/jns.1986.65.4.0476
  - PMID: 3760956

**Key Validation Studies:**
- Lawton MT, Kim H, McCulloch CE, Mikhak B, Young WL. "A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery." *Neurosurgery.* 2010;66(4):702-713.
  - DOI: 10.1227/01.NEU.0000367555.16733.E1
  - PMID: 20190666

- Starke RM, Komotar RJ, Hwang BY, et al. "Treatment guidelines for cerebral arteriovenous malformation microsurgery." *Br J Neurosurg.* 2009;23(4):376-386.
  - DOI: 10.1080/02688690902935665
  - PMID: 19637010

**Clinical Application:**
- Predicts surgical morbidity and mortality for brain AVMs
- Guides treatment modality selection (surgery vs. radiation vs. observation)
- Validated in multiple large series

**Grading Components:**
1. **Size:**
   - Small (<3cm): 1 point
   - Medium (3-6cm): 2 points
   - Large (>6cm): 3 points

2. **Eloquence:**
   - Non-eloquent: 0 points
   - Eloquent: 1 point

3. **Venous Drainage:**
   - Superficial only: 0 points
   - Deep component: 1 point

**Risk Stratification:**
- **Grade I-II:** Low risk (<5% morbidity)
- **Grade III:** Moderate risk (10-15% morbidity)
- **Grade IV-V:** High risk (20-30% morbidity)

**Eloquent Areas:** Sensorimotor cortex, language cortex, visual cortex, thalamus, hypothalamus, internal capsule, brainstem, cerebellar peduncles, deep cerebellar nuclei

---

## Pathology-Specific Prognostic Tools

### 13. IDH Mutation Status (Glioblastoma)

**Clinical Significance:**
- Korshunov A, Ryzhova M, Hovestadt V, et al. "Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers." *Acta Neuropathol.* 2015;129(5):669-678.
  - DOI: 10.1007/s00401-015-1405-4
  - PMID: 25750066

- Yan H, Parsons DW, Jin G, et al. "IDH1 and IDH2 mutations in gliomas." *N Engl J Med.* 2009;360(8):765-773.
  - DOI: 10.1056/NEJMoa0808710
  - PMID: 19228619

**Prognostic Value:**
- IDH-mutant glioblastoma: Median survival 31 months
- IDH-wildtype glioblastoma: Median survival 15 months

---

### 14. MGMT Promoter Methylation (Glioblastoma)

**Clinical Significance:**
- Hegi ME, Diserens AC, Gorlia T, et al. "MGMT gene silencing and benefit from temozolomide in glioblastoma." *N Engl J Med.* 2005;352(10):997-1003.
  - DOI: 10.1056/NEJMoa043331
  - PMID: 15758010

**Prognostic Value:**
- MGMT methylated: 23.4 months median survival with TMZ
- MGMT unmethylated: 12.6 months median survival with TMZ

---

### 15. WHO Grade (Gliomas)

**Current Classification:**
- Louis DN, Perry A, Wesseling P, et al. "The 2021 WHO Classification of Tumors of the Central Nervous System: a summary." *Neuro Oncol.* 2021;23(8):1231-1251.
  - DOI: 10.1093/neuonc/noab106
  - PMID: 34185076

**Grades:**
- **Grade 1:** Well-differentiated, slow-growing, curable with surgery
- **Grade 2:** Infiltrative, may recur, higher recurrence risk
- **Grade 3:** Malignant, anaplastic features, requires aggressive treatment
- **Grade 4:** Highly malignant, rapid growth, poor prognosis (GBM)

---

## Implementation Guidelines

### Using Clinical Scores in DCS

The DCS system implements these clinical scoring systems in several modules:

1. **Extraction Phase** (`src/services/extraction.js`):
   - Automatically extracts scores from clinical notes
   - Identifies score type, value, date, and context

2. **Functional Evolution Tracking** (`src/utils/functionalEvolution.js`):
   - Tracks score changes over time (lines 72-207)
   - Analyzes trajectory patterns (lines 416-520)
   - Compares with prognostic expectations (lines 621-655)

3. **Intelligence Hub** (`src/services/intelligenceHub.js`):
   - Integrates scores into clinical intelligence
   - Provides quality assessment
   - Identifies trends and patterns

### Best Practices for Implementation

1. **Always cite the source** when reporting clinical scores
2. **Include interpretation guidelines** for non-specialist readers
3. **Compare serial scores** when available to show trajectory
4. **Provide prognostic context** based on published literature
5. **Note limitations** of score application in specific contexts

---

## Clinical Validation

### Validation Strategy for DCS

1. **Score Recognition Accuracy:**
   - Target: >95% accuracy in identifying correct score type
   - Validation: Comparison with manual chart review

2. **Value Extraction Accuracy:**
   - Target: >98% accuracy for numeric scores
   - Validation: Expert annotation gold standard

3. **Temporal Accuracy:**
   - Target: >90% accuracy in date association
   - Validation: Timeline reconstruction verification

4. **Prognostic Application:**
   - Target: Appropriate use of published outcome data
   - Validation: Expert review of prognostic statements

---

## Additional Resources

### Online Calculators and Tools

1. **mRS Calculator:** https://www.mdcalc.com/modified-rankin-scale-neurologic-disability
2. **NIHSS Calculator:** https://www.mdcalc.com/nih-stroke-scale-score-nihss
3. **Hunt-Hess Scale:** https://www.mdcalc.com/hunt-hess-classification-subarachnoid-hemorrhage
4. **WFNS Scale:** https://www.mdcalc.com/wfns-classification-subarachnoid-hemorrhage
5. **Spetzler-Martin Grade:** https://www.mdcalc.com/spetzler-martin-grading-system-avms

### Clinical Guidelines

1. **American Heart Association/American Stroke Association:**
   - Stroke outcome measures recommendations
   - https://www.ahajournals.org/stroke

2. **American Spinal Injury Association:**
   - International Standards for Neurological Classification of SCI
   - https://asia-spinalinjury.org/

3. **National Comprehensive Cancer Network (NCCN):**
   - CNS cancer guidelines with performance status requirements
   - https://www.nccn.org/

---

## Version History

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | October 2025 | Initial comprehensive reference document |

---

## Contributors

- **Clinical Content:** Neurosurgery Clinical Team
- **Literature Review:** Evidence-Based Medicine Committee
- **Technical Implementation:** DCS Development Team

---

## Disclaimer

This document provides literature citations and clinical context for scoring systems implemented in the Discharge Summary Generator. Clinical decision-making should always be based on individual patient assessment and clinical judgment. Scores should be interpreted in the appropriate clinical context.

For questions or updates to this reference guide, please contact the DCS Clinical Review Committee.

---

**Last Reviewed:** October 2025
**Next Review Date:** January 2026
